Literature DB >> 10537350

Relationship between intratumoral dihydropyrimidine dehydrogenase activity and gene expression in human colorectal cancer.

H Uetake1, W Ichikawa, T Takechi, M Fukushima, Z Nihei, K Sugihara.   

Abstract

Dihydropyrimidine dehydrogenase (DPD) is the rate-limiting enzyme for 5-fluorouracil catabolism. In this study, both the enzymatic activity and mRNA level of DPD were estimated in the tumor tissue and adjacent normal mucosa of 51 patients with colorectal cancer. Although no significant difference in enzymatic activity was observed between tumor tissue and normal mucosa (70.4 and 70.7 pmol/min/mg protein, respectively), the mRNA level in normal mucosa was significantly higher than that in tumor tissue (1.37 and 0.39, respectively; P<0.01). A linear relationship was noted between DPD activity and the DPD mRNA level in cancerous tissue (r(s) = 0.714, P<0.001). Thus, the DPD mRNA level as determined by reverse transcription-PCR can be used to indicate the DPD activity of colorectal cancers.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10537350

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  10 in total

1.  Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers.

Authors:  Bart A W Jacobs; Maarten J Deenen; Dick Pluim; J G Coen van Hasselt; Martin D Krähenbühl; Robin M J M van Geel; Niels de Vries; Hilde Rosing; Didier Meulendijks; Artur M Burylo; Annemieke Cats; Jos H Beijnen; Alwin D R Huitema; Jan H M Schellens
Journal:  Br J Clin Pharmacol       Date:  2016-06-03       Impact factor: 4.335

2.  Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study.

Authors:  Agustin A Garcia; John A Blessing; Kathleen M Darcy; Heinz Josef Lenz; Wu Zhang; Ed Hannigan; David H Moore
Journal:  Gynecol Oncol       Date:  2006-10-17       Impact factor: 5.482

3.  The increasing role of pharmacogenetics in the treatment of gastrointestinal cancers.

Authors:  Suayib Yalçin
Journal:  Gastrointest Cancer Res       Date:  2009-09

4.  Differences in dihydropyrimidine dehydrogenase activities between gastric and colorectal cancer.

Authors:  Bunzo Nakata; Kazuya Muguruma; Shigehito Yamagata; Kiyotaka Yukimoto; Kiyoshi Maeda; Yukio Nishiguchi; Masaichi Ohira; Yasuyuki Kato; Kosei Hirakawa
Journal:  Dig Dis Sci       Date:  2004-01       Impact factor: 3.199

Review 5.  Molecular predictors of treatment and outcome in colorectal cancer.

Authors:  Syma Iqbal; Heinz-Josef Lenz
Journal:  Curr Gastroenterol Rep       Date:  2003-10

Review 6.  Determinants of prognosis and response to therapy in colorectal cancer.

Authors:  S Iqbal; H J Lenz
Journal:  Curr Oncol Rep       Date:  2001-03       Impact factor: 5.945

7.  Expression levels of thymidylate synthase, thymidylate phosphorylase and dihydropyrimidine dehydrogenase in head and neck squamous cell carcinoma: preliminary study.

Authors:  K Aubry; J L Labourey; J P Bessède; N Tubiana-Mathieu; M Rigaud
Journal:  Clin Med Oncol       Date:  2008-01-22

8.  CPT-11 alters the circadian rhythm of dihydropyrimidine dehydrogenase mRNA in mouse liver.

Authors:  M Shimizu; T Tamura; Y Yamada; Y Akiyama; N Saijo; K Nishio
Journal:  Jpn J Cancer Res       Date:  2001-05

Review 9.  Predictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of Options.

Authors:  Daniela Rodrigues; Adhemar Longatto-Filho; Sandra F Martins
Journal:  Biomed Res Int       Date:  2016-08-01       Impact factor: 3.411

Review 10.  DPYD and Fluorouracil-Based Chemotherapy: Mini Review and Case Report.

Authors:  Theodore J Wigle; Elena V Tsvetkova; Stephen A Welch; Richard B Kim
Journal:  Pharmaceutics       Date:  2019-05-01       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.